Related Targets |
Target |
Mechanism Respiratory syncytial virus F protein modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date31 May 2023 |
Target |
Mechanism Respiratory syncytial virus F protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date31 Oct 2022 |
Target |
Mechanism Respiratory syncytial virus F protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date19 Jun 1998 |
Start Date07 Feb 2024 |
Sponsor / Collaborator Pfizer Inc. [+2] |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date01 Jan 2024 |
Sponsor / Collaborator Yale University [+1] |